Gaps in surveillance, testing, sequencing, and vaccination for COVID-19 could create the perfect storm for a new variant.
Pharmaceutical companies could be made to disclose prices and deals agreed for any products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord reviewed by Reuters.
RSV, influenza, COVID-19 and monkeypox have dominated vaccine discussions this year, but vaccines are also being developed for a host of other infectious diseases.
Lebanon took delivery on Monday of its first vaccines to combat a worsening cholera outbreak – together with sharply worded criticism of the crisis-hit country’s crumbling public health infrastructure from donor nation France.
The potential deal with the U.S. Department of Defense (DoD) would see Moderna’s mRNA technology being used to develop a vaccine targeting the Ebola strain responsible for the disease’s outbreak in Uganda, according to a report.
The number of confirmed Ebola cases in Uganda has risen to 109 and the outbreak has claimed 30 lives, Health Minister Jane Ruth Aceng said on Wednesday, adding that the government was setting up an additional treatment center.
Another wave of COVID-19 infections may have begun in Europe as cases begin to tick up across the region, the World Health Organization and European Centre for Disease Prevention and Control (ECDC) said on Wednesday.
The pharmaceutical giant, still riding high on the sales of Comirnaty and Paxlovid, is looking to a future of innovative oncology drugs and vaccines based on mRNA technology.
Alexion has boosted AstraZeneca’s rare disease expertise while the company has experienced success in oncology and COVID-19.
With a range of heavy-hitting speakers, including former President Barack Obama, attendees gathered at the Brooklyn Navy Yard to learn more about the possibilities of the future of healthcare and biomedicine, and reflect on lessons learned from the past.